Patient Health Timeline
🔬 ETHOS Clinical Synopsis
67-year-old male with severe COPD (GOLD III), T2DM, HTN, and AF presenting with progressive dyspnea and new peripheral edema. Pattern consistent with early COPD exacerbation with possible HF decompensation component. High hospitalization risk trajectory identified.
🫁 Respiratory Status
FEV142% pred ↓
Exacerbations (12mo)2 requiring hosp.
CAT Score (est.)24 (High)
❤️ Cardiovascular Status
BNP245 pg/mL ↑
AF ControlRate-controlled
EdemaNew bilateral
⚠️ ETHOS Priority Alerts
High 90-day hospitalization risk: 44%
Driven by: declining FEV1, 2 recent hospitalizations, elevated BNP, new edema
Consider diuretic optimization
Elevated BNP + new edema may indicate subclinical HF decompensation
Eligible for ABM-funded COPD trial
92% criteria match for BREATHE-PL study (see Trial Matching tab)
Personalized Risk Trajectories
ETHOS projections based on 47 encounters, 234 lab results
90-Day Hospitalization
44%
vs. 18% population avg
90-Day Exacerbation
51%
vs. 22% population avg
90-Day Mortality
6%
vs. 2% population avg
Key Risk Drivers (SHAP Analysis)
FEV1 42% predicted
+28%
2 hospitalizations/12mo
+22%
BNP 245 pg/mL
+15%
New peripheral edema
+12%
Age 67
+8%
👥 ETHOS Trial Matching Engine
Automatically screened against 47 active ABM-funded and industry-sponsored trials. Found 2 potential matches.
ABM-Funded
ABM-2025-COPD-047
BREATHE-PL: Triple Therapy vs. Dual Bronchodilation in Severe COPD
ABM / Gdański Uniwersytet Medyczny • Phase III
92%
match
✓
Age 40-75
✓
COPD Gold III-IV
✓
≥1 exacerb./12mo
✓
FEV1 <50%
✓
No malignancy
Industry
IND-2025-DM-112
SGLT2i Cardioprotection in T2DM with Preserved EF
Boehringer Ingelheim • Phase IV
78%
match
✓
T2DM diagnosis
✓
Age ≥50
✓
eGFR ≥45
✓
Not on SGLT2i
✗
HbA1c 7-10%
7.8% borderline
Auto-Generated Visit Documentation
ETHOS draft • Review and edit as needed
AMBULATORY VISIT NOTE
Date: 04.12.2025 | Facility: NZOZ Centrum Medyczne
CHIEF COMPLAINT:
Progressive dyspnea on exertion × 2 weeks, new bilateral ankle edema, increased morning cough with sputum production.
HISTORY OF PRESENT ILLNESS:
67-year-old male with known severe COPD (GOLD III), T2DM, HTN, and atrial fibrillation presenting with worsening respiratory symptoms. Patient reports increased breathlessness with activities previously tolerated (walking <100m), accompanied by new bilateral lower extremity swelling noted over past week. Morning cough has become more productive with whitish sputum. No fever, chest pain, or hemoptysis reported.
RELEVANT HISTORY (ETHOS-summarized from P1):
• 2 COPD exacerbations requiring hospitalization in past 12 months
• Heart failure hospitalization June 2024
• Most recent FEV1: 42% predicted (declining from 48% in 2024)
• Recent labs: HbA1c 7.8%, eGFR 58, BNP 245 pg/mL (elevated)
CURRENT MEDICATIONS:
Tiotropium 18mcg daily, Metformin 1000mg BID, Lisinopril 20mg daily, Apixaban 5mg BID
ASSESSMENT:
1. COPD exacerbation, likely early/moderate
2. Possible HF decompensation component - new edema, elevated BNP
3. ETHOS 90-day hospitalization risk: 44% (high)
PLAN:
1. Initiate oral corticosteroid burst (prednisone 40mg × 5 days)
2. Add furosemide 20mg daily for volume management, monitor weight daily
3. Sputum culture if purulent; consider antibiotics if bacterial etiology
4. Cardiology referral for HF optimization
5. Pulmonology follow-up in 2 weeks; sooner if worsening
6. Patient counseled on warning signs requiring ED evaluation
7. Discussed eligibility for BREATHE-PL trial (ABM-2025-COPD-047) - patient interested, referred to research coordinator
— Draft generated by ETHOS from P1 data + pre-visit intake. Physician review required. —
⏱️
Estimated time saved: 8-12 minutes